Severe COVID-19 trial enrollment reaches 178 patients; interim analysis expected in Q3 At the FDA’s suggestion, planning to...
InflaRx
Submitted a Special Protocol Assessment to the FDA for Phase III program evaluating vilobelimab in Hidradenitis Suppurativa (HS) in Q1...
